More than 120 million adults in the United States now meet the clinical definition of cardiovascular disease, a figure that places the prevalence rate near 47 percent of the adult population. That number, drawn primarily from federal blood pressure, lipid, and glucose measurements collected between August 2021 and August 2023, reflects a reality shaped as much by how hypertension is defined as by how many people are actually getting sicker. The distinction matters because it determines who qualifies for treatment, who gets screened, and how billions of dollars in prevention funding are allocated.
How Redefined Blood Pressure Thresholds Drove the Count Upward
The single largest contributor to the “nearly half” figure is hypertension, and the way hypertension is counted changed sharply in 2017. Before that year, the clinical threshold for high blood pressure sat at 140/90 mmHg. The 2017 ACC/AHA guideline revision lowered it to 130/80 mmHg, instantly reclassifying millions of adults who had previously been considered borderline. A peer-reviewed cross-sectional study in NHANES analyses quantified the effect: the guideline change substantially increased the proportion of U.S. adults labeled hypertensive and eligible for antihypertensive treatment. That single definitional shift, applied to the same underlying population measurements, moved the national prevalence estimate from roughly one in three adults to nearly one in two.
The American Heart Association’s 2024 Heart Disease and Stroke Statistics report, published in Circulation, defines cardiovascular disease broadly to include hypertension alongside coronary heart disease, heart failure, and stroke. Because hypertension accounts for the vast majority of cases within that umbrella, the AHA’s aggregate prevalence estimate rises and falls with the blood pressure threshold in use. The report draws heavily on repeated cycles of the National Health and Nutrition Examination Survey (NHANES), the same nationally representative dataset that underpins CDC surveillance products.
What NHANES Measurements From 2021 to 2023 Actually Show
The CDC’s National Center for Health Statistics summarized the latest numbers in Data Brief 540, which reports on cardiovascular risk factors among adults based on NHANES examinations conducted from August 2021 through August 2023. The brief uses measured blood pressure readings, cholesterol panels, and fasting glucose values collected during in-person visits rather than self-reported survey answers. That methodology lends more clinical weight than telephone-based polls, but the data carry an important limitation: they capture a snapshot of risk factor prevalence, not a count of new diagnoses, heart attacks, or strokes.
Within that snapshot, hypertension dominates. When the lower 2017 threshold is applied, nearly half of U.S. adults in the examined period meet criteria for high blood pressure. Elevated LDL cholesterol and impaired fasting glucose add further risk, but they do not drive the headline cardiovascular disease prevalence in the same way. Instead, they cluster with hypertension in many of the same individuals, compounding risk rather than dramatically expanding the pool of affected adults.
A separate peer-reviewed analysis of the same survey cycles compared hypertension prevalence, awareness, and control between the pre‑pandemic period of 2017 through March 2020 and the post‑pandemic window of August 2021 through August 2023. That study, published in the Journal of the American Heart Association, found that hypertension rates rose after the pandemic with only modest gains in awareness and limited improvement in control. The pattern raises a difficult question: did the pandemic itself worsen cardiovascular health, or did disruptions in routine care simply reduce the number of people whose blood pressure was being effectively managed?
An earlier CDC analysis, Data Brief 364, had already established hypertension prevalence among U.S. adults using NHANES 2017–2018 data and the post‑guideline threshold. Comparing that baseline to the 2021–2023 figures shows that measured prevalence has remained in a broadly similar range. The underlying distribution of blood pressure in the population does not appear to have shifted enough to explain a sudden leap from one‑third to nearly one‑half of adults on its own. The large headline number, in other words, was largely baked in once the 2017 threshold took effect.
Guideline Mechanics vs. True Disease Acceleration
The tension at the center of this statistic is whether the country is experiencing a genuine surge in cardiovascular illness or whether measurement conventions are doing most of the work. Both can be partly true at the same time, but the policy consequences differ. If the rise is primarily definitional, the response should focus on refining treatment guidelines so that newly classified patients receive interventions proportional to their actual risk. If the rise reflects real biological deterioration across the population, the response demands broader investment in prevention, from dietary programs and physical activity initiatives to expanded primary care access.
The available NHANES data lean toward the definitional explanation for the bulk of the increase. Measured blood pressure distributions in adults have not shifted enough between survey cycles to account for a jump from one‑third to nearly one‑half prevalence on their own. The 2017 guideline revision, by contrast, produced exactly that magnitude of change by moving the diagnostic line downward. The BMJ modeling work confirmed this mechanism by showing how many additional adults crossed the new threshold without any change in their actual readings.
That said, the post‑pandemic comparison does show real erosion in hypertension control rates. Fewer adults with high blood pressure had it managed to target levels in the 2021–2023 cycle than in the years immediately preceding the pandemic, even as overall prevalence edged upward. Missed primary care visits, delayed medication refills, and disruptions to community‑based screening likely all played a role. Those trends point to a subtler form of disease acceleration: not a sudden shift in physiology across the whole population, but a deterioration in the systems that keep chronic conditions in check.
Implications for Patients and Policy
For individual patients, the lower threshold means more people are told they have hypertension, often on the basis of a relatively small elevation in blood pressure. For some, that label can prompt earlier lifestyle changes and closer monitoring that prevent heart attacks and strokes. For others, especially those at low absolute risk, it may lead to additional clinic visits, anxiety, or medication side effects with limited benefit. Clinicians are left to navigate a gray zone where guideline‑defined disease does not always align neatly with a patient’s lived experience of illness.
At the population level, counting hypertension as cardiovascular disease has powerful implications. It brings attention and funding to a major modifiable risk factor, supporting programs that promote sodium reduction, healthier food environments, and better access to affordable medications. Yet it can also obscure important distinctions. A 35‑year‑old with mildly elevated blood pressure and no other risk factors is not at the same near‑term risk as a 70‑year‑old with prior myocardial infarction, even though both are swept into the same “cardiovascular disease” category in national statistics.
Policymakers and health systems must therefore read the “47 percent” figure with nuance. It signals a vast burden of cardiovascular risk, much of it driven by a definitional change that reclassified people whose physiology has not markedly worsened. At the same time, the erosion in hypertension control and the persistence of high cholesterol and abnormal glucose in NHANES data underscore that the underlying problem is real. The task ahead is to use these measurements not simply to count more patients, but to target prevention and treatment where they will avert the most heart attacks, strokes, and premature deaths.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
